



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2013

---

## **Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome**

Oberwahrenbrock, T ; Ringelstein, M ; Jentschke, S ; Deuschle, K ; Klumbies, K ; Bellmann-Strobl, J ; Harmel, J ; Ruprecht, K ; Schippling, S ; Hartung, Hans-Peter ; Aktas, O ; Brandt, A U ; Paul, F

**Abstract:** **BACKGROUND:** Axonal and neuronal damage are widely accepted as key events in the disease course of multiple sclerosis. However, it has been unclear to date at which stage in disease evolution neurodegeneration begins and whether neuronal damage can occur even in the absence of acute inflammatory attacks. **OBJECTIVE:** To characterize inner retinal layer changes in patients with clinically isolated syndrome (CIS). **METHOD:** 45 patients with CIS and age- and sex-matched healthy controls were investigated using spectral domain optical coherence tomography. Patients' eyes were stratified into the following categories according to history of optic neuritis (ON): eyes with clinically-diagnosed ON (CIS-ON), eyes with suspected subclinical ON (CIS-SON) as indicated by a visual evoked potential latency of >115ms and eyes unaffected by ON (CIS-NON). **RESULTS:** CIS-NON eyes showed significant reduction of ganglion cell- and inner plexiform layer and a topography similar to that of CIS-ON eyes. Seven eyes were characterized as CIS-SON and likewise showed significant retinal layer thinning. The most pronounced thinning was present in CIS-ON eyes. **CONCLUSION:** Our findings indicate that retinal pathology does occur already in CIS. Intraretinal layer segmentation may be an easily applicable, non-invasive method for early detection of retinal pathology in patients unaffected by ON.

DOI: <https://doi.org/10.1177/1352458513489757>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-86854>

Journal Article

Accepted Version

Originally published at:

Oberwahrenbrock, T; Ringelstein, M; Jentschke, S; Deuschle, K; Klumbies, K; Bellmann-Strobl, J; Harmel, J; Ruprecht, K; Schippling, S; Hartung, Hans-Peter; Aktas, O; Brandt, A U; Paul, F (2013). Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. *Multiple Sclerosis*, 19(14):1887-1895.

DOI: <https://doi.org/10.1177/1352458513489757>

# **Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome**

Timm Oberwahrenbrock<sup>1\*</sup>, Marius Ringelstein<sup>2\*</sup>, Simon Jentschke<sup>1</sup>, Katrin Deuschle<sup>1,3</sup>, Katharina Klumbies<sup>1</sup>, Judith Bellmann-Strobl<sup>1,3</sup>, Jens Harmel<sup>2</sup>, Klemens Ruprecht<sup>3</sup>, Sven Schippling<sup>4</sup>, Hans-Peter Hartung, MD<sup>2</sup>, Orhan Aktas, MD<sup>2</sup>, Alexander U. Brandt, MD<sup>1§</sup> and Friedemann Paul, MD<sup>1,3§</sup>

1) NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany

2) Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

3) Department of Neurology, Charité University Medicine Berlin, Berlin, Germany

4) Department of Neuroimmunology and Clinical Multiple Sclerosis Research, Neurology Clinic, University Medical Center Zurich, Zurich, Switzerland

\*) Equally contributing first authors in alphabetical order

§) Equally contributing senior authors in alphabetical order

## **Address for correspondence:**

Dr. Friedemann Paul, NeuroCure Clinical Research Center, Charité University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany, Tel.: +49 30 450 539705, Fax +49 30 450 539915, Email: [friedemann.paul@charite.de](mailto:friedemann.paul@charite.de)

Keywords: clinically isolated syndrome, optical coherence tomography, retinal nerve fiber layer, retinal ganglion cell layer

## **Abstract**

Background: Axonal and neuronal damage are widely accepted as key events in the disease course of multiple sclerosis. However, it has been unclear to date at which stage in disease evolution neurodegeneration begins and whether neuronal damage can occur even in the absence of acute inflammatory attacks.

Objective: To characterize inner retinal layer changes in patients with clinically isolated syndrome (CIS).

Method: 45 patients with CIS and age- and sex-matched healthy controls were investigated using spectral domain optical coherence tomography. Patients' eyes were stratified into the following categories according to history of optic neuritis (ON): eyes with clinically diagnosed ON (CIS-ON), eyes with suspected subclinical ON (CIS-SON) as indicated by a visual evoked potential latency of  $>115$ ms and eyes unaffected by ON (CIS-NON).

Results: CIS-NON eyes showed significant reduction of ganglion cell- and inner plexiform layer and a topography similar to that of CIS-ON eyes. Seven eyes were characterized as CIS-SON and likewise showed significant retinal layer thinning. The most pronounced thinning was present in CIS-ON eyes.

Conclusion: Our findings indicate that retinal pathology does occur already in CIS. Intraretinal layer segmentation may be an easily applicable, non-invasive method for early detection of retinal pathology in patients unaffected by ON.

## Introduction

Multiple sclerosis is an autoimmune disorder of the central nervous system that often manifests with optic neuritis (ON) as well as motor, sensory or cerebellar deficits in its earliest stage.<sup>1</sup> Current diagnostic criteria for MS require proof of dissemination of lesions or attacks in time and space.<sup>2</sup> In every day clinical practice, patients presenting with a first clinical event that is highly indicative of MS are often instead diagnosed with a clinically isolated syndrome (CIS) or “possible” MS.<sup>3</sup> A confirmed diagnosis of MS is possible once additional attacks or lesions present, as is the case for a significant proportion of such patients.<sup>2</sup>

In light of this, pinpointing the aspects of CIS that are most predictive for subsequent diagnosis with MS has high priority<sup>3</sup> so that patients at risk can be identified.

Diagnosing MS as early as possible and thus allowing for the widest range of therapeutic options, is therefore highly in the patients’ interest, in particular as irreversible axonal and neuronal injury is a key aspect and correlate of disability in MS in early disease stages.<sup>3–5</sup>

One easily accessible means of assessing neuroaxonal damage in MS is the investigation of the retina. Optical coherence tomography (OCT) has shown specific retinal alterations in MS patients:<sup>6</sup> The retinal nerve fiber layer (RNFL) is reduced in MS,<sup>7</sup> not only in eyes with a history of ON<sup>8</sup> but also in eyes without any previous clinical event of ON.<sup>9,10</sup> Additionally, microcystic macular edema (MME) in the inner nuclear layer (INL) has been reported in a subset of MS patients.<sup>11</sup> Although MME might not be specific to MS but instead ON dependent,<sup>12</sup> the INL has become a key focus of clinical investigation of MS pathology after a postmortem histopathology study reported neuronal loss in the INL.<sup>13,14</sup>

Additionally, retinal changes in MS do not merely reflect the visual system, but potentially also overall disease pathology. RNFL thinning correlates closely with brain atrophy,<sup>15–17</sup> and with reduction of N-acetyl-aspartate as marker of neuroaxonal integrity in the visual cortex.<sup>18</sup>

These findings suggest that the retina and, in particular, intraretinal layers may be an effective means of detecting subtle neuronal and axonal damage already present in CIS. To investigate this theory, we performed a cross-sectional study analyzing intraretinal changes in CIS patients. We were especially interested in retinal pathology in eyes that had not suffered from previous ON and therefore applied a rigorous classification of eyes not only on clinical assessments but also visual evoked potentials (VEP).

## **Methods**

### Study participants

Patients were prospectively recruited from outpatient clinics at two university medical centers (Berlin and Düsseldorf). Inclusion criteria were clinical and paraclinical (MRI, CSF, EP) diagnosis of CIS suggestive of MS after relevant differential diagnoses had been ruled out and age between 18 and 65 years.<sup>2</sup> Patients received MRI to exclude the possibility that the disease had developed into MS since first diagnosis of CIS. Neurological disability was assessed according to the Expanded Disability Status Scale (EDSS).<sup>19</sup> A history of ON was diagnosed by a treating physician and was cross-checked using medical records. Patients with a refractive error of more than  $\pm 5.0$  diopters or with any history of eye disease that could impact OCT measurements (i.e. glaucoma) were excluded. A second exclusion criterion was steroid therapy within 30 days prior to examination. A group of healthy controls

matched by age ( $\pm 3$  years) and gender was recruited from patients' family members, medical staff or volunteers. Both centres assessed the matched controls to their patients. To exclude potential centre effects, we additionally performed centre specific analysis or included centre as covariate. In these analyses centre did not have a significant effect (data not shown). Local ethics committees approved the study and all participants gave written, informed consent.

#### Visual evoked potentials

VEP were either performed during the clinical work-up or as part of the study protocol prior to or on the same day as the OCT assessment. We used the P100 latency values as a parameter to prove optic nerve conduction slowing potentially related to a history of ON. VEP amplitude was not analyzed because the two centers involved in the study performed VEP using different devices in a non-standardized manner.

#### Optical coherence tomography

Experienced operators performed OCT on undilated eyes using Heidelberg Spectralis SD-OCT (Heidelberg Engineering, Germany). All scans were checked for appropriate image quality. All participants were examined using the peripapillary ring scan, which measures RNFL thickness (pRNFL) around the optic nerve head in a circle with an angle of  $12^\circ$ , resulting in a diameter of 3.4 mm (example shown in Figure 1A). Macular volume was assessed by a custom scan comprising 61 vertical B-scans (each with 768 A-Scans, Automatic Real-Time (ART) = 13 frames) with a scanning angle of  $30^\circ \times 25^\circ$  focusing on the fovea. Using this scan, TMV and intra-retinal layers thicknesses were determined within a cylinder of 6 mm diameter (Figure 1B).

#### Intraretinal layer segmentation

Heidelberg Engineering provided beta software that employed a multilayer segmentation algorithm for macular volume scans. To analyze the inner retinal layers, a subset of B-scans were segmented and manually corrected by an experienced assessor in a blinded fashion. The multilayer analysis was performed on the central B-scan through the fovea and on six B-scans each in nasal and temporal direction. Manual correction of automatically segmented B-scans is a time consuming step. As a compromise we manually corrected every fourth B-scan, thus analysing an area largely covering the 6 mm diameter ETDRS grid with a distance between adjacent B-scans of approximately 500  $\mu\text{m}$ . For the combined analysis of both eyes, thickness maps of the left eye were mirrored vertically to match the topology of the right eye. The mean thickness maps within each of the study groups were calculated for the four innermost retinal layers: macular RNFL (mRNFL), ganglion cell layer (GCL), inner plexiform layer (IPL) and INL (Figure 1C). Because differentiating between GCL and IPL proved to be a hurdle, we used the combined thickness of GCL and IPL (GCIPL). Please see the supplementary data for individual analyses of GCL and IPL. By subtracting the group-specific mean thickness maps we produced spatial difference maps (Figure 3), in which negative values indicate a thinning of the patients' group compared to matched healthy controls, whereas positive values indicated thickening.

### Statistical analysis

Generalized estimation equation models (GEE) accounting for within-subject inter-eye effects were used to compare OCT results between the study cohorts. For the subgroup analysis, only controls that were matched to the respective CIS patients' eyes (NON, SON, ON) were used. Correlations between VEP and OCT results were performed by linear regression. All statistical analyses were performed and all figures

were created using R version 2.15.0. Statistical significance was established at  $P < 0.05$ .

## Results

### Study participants

45 patients (Berlin 29, Düsseldorf 16) were enrolled and compared to matched healthy controls (Berlin 29, Düsseldorf 16). All patients were diagnosed with CIS at the time of OCT examination and diagnosis and non-progression towards MS was confirmed by means of MRI. 17 patients had unilateral optic neuritis (7 on the right, 10 on the left eye), 14 patients presented with spinal cord symptoms. 6 patients experienced relapses with findings suggestive of infratentorial brain lesions, in 7 patients supratentorial signs were found, and one patient exhibited both supratentorial and spinal clinical signs. Examination of one patient's eye did not pass the quality criteria due to image artifacts and was excluded. Demographic and clinical data are summarized in Table 1.

### ON classification according to VEP latency and correlation to standard OCT results

As a clinical diagnosis of ON may have been missed by patients or physicians, we created another category of subclinical (or suspected) ON in eyes without a clinical ON history, as assessed by VEP. In addition to the group of confirmed ON eyes (CIS-ON), we defined a group of suspected ON eyes (CIS-SON), defined as eyes with prolonged P100 latency of over 115 ms but, as stated above, without a clinical history of ON. The latter value of a 115 ms limit for normal eyes is in accordance with literature<sup>20</sup> and proved an effective means of distinguishing between eyes diagnosed with ON and unaffected eyes (Figure 2A and 2B). In total, seven eyes were classified as CIS-SON. Both eyes of two patients were classified as suspected ON and all other



CIS-SON eyes were contralateral to CIS-ON eyes. Figure 2A shows the correlation between P100 latencies and pRNFL thickness, while Figure 2B is a graph of the relationship between the TMV and the VEP results. Linear regression showed significant correlation between pRNFL and P100 VEP latencies in all CIS eyes ( $R^2 = 0.243$ ,  $P < 0.001$ ) and in CIS-NON eyes ( $R^2 = 0.065$ ,  $P = 0.039$ ) but not in CIS-SON and CIS-ON eyes. Similarly, TMV correlated significantly to P100 latencies for all CIS eyes ( $R^2 = 0.124$ ,  $P < 0.001$ ), but not for the other subgroups.

#### pRNFL and TMV comparison

When compared to the corresponding age- and sex-matched controls, pRNFL thickness was reduced in CIS-ON ( $P < 0.001$ ) and CIS-SON ( $P = 0.014$ ) but not in CIS-NON eyes ( $P = 0.636$ ) (Figure 2C). Analysis of macular scans revealed significant TMV reduction in CIS-ON eyes ( $P < 0.001$ ) and, importantly, also in CIS-NON eyes ( $P = 0.031$ ) versus controls (Figure 2D). TMV reduction in the 7 CIS-SON eyes was not significant.

#### Intraretinal multilayer segmentation

The mean macular thickness values for inner retinal layers (mRNFL, GCIPL, INL) of the different groups are summarized in Table 2. A graphical representation of the spatial changes of CIS patients compared to the matching controls is given in Figure 3.

Analysis of the central macular area (6 mm in diameter around the fovea) showed significant reduction in mRNFL thickness in CIS-ON eyes, but not for CIS-SON and CIS-NON in comparison to matched controls (Table 2). Spatial difference maps showed that mRNFL thinning was most prominent in close proximity to the optic nerve head (Figure 3A, white arrows). Here, even for CIS-NON eyes mRNFL thinning

was visible very close to the optic nerve head. It should be noted that macular volume scans are not designed to investigate the papillary region and that this area is highly penetrated by blood vessels, potentially causing segmentation errors; thus, the mRNFL results have to be evaluated with caution.

All patient groups showed reduced GCIPL thickness compared to the matched healthy controls. Spatial differences of the GCIPL were found in the perimacular region (Figure 3B) and statistical analysis of the GCIP confirmed that the thickness in this area was significantly reduced for all patient groups compared to controls (Table 2). The thinning in CIS-ON and CIS-SON eyes was more pronounced than in the CIS-NON group while the spatial distribution of changes was similar. Please refer to the supplementary material for detailed data on the analysis of the GCL and IPL individually.

Analogous to pRNFL and TMV we analysed a potential correlation between VEP latencies and intraretinal layer thicknesses: mRNFL ( $R^2 = 0.203$ ,  $P < 0.001$ ) and GCIP ( $R^2 = 0.315$ ,  $P < 0.001$ ) were significantly correlated to VEP latencies (supplementary figure 2). There was no correlation of intraretinal layer thicknesses or VEP latencies with symptom onset in the CIS-NON group (supplementary figure 3).

## **Discussion**

We analysed intraretinal changes in a cohort of CIS patients, which included both eyes with confirmed previous ON, eyes with suspected ON, and eyes without evidence of ON compared to age- and sex-matched healthy controls. Notably, we identified significant thinning of GCIPL in the eyes of CIS patients without any clinical history of ON or suspected previous subclinical ON as determined by VEP changes. A supplementary analysis using distinct GCL and IPL thicknesses localized this

GCIPL thinning to the GCL in CIS-NON patients. Additionally and as expected, eyes with a confirmed history of ON showed an even more pronounced thinning of retinal layers. In contrast, INL appeared unaltered. Our data indicate that retinal neuronal damage can accompany CIS independently of a prior history of ON.

Three previous studies have investigated retinal changes in CIS patients: The first study failed to detect pRNFL or TMV reduction in the eyes of CIS patients without prior ON.<sup>21</sup> A second study reported no retinal damage in the eyes of patients with isolated unilateral ON.<sup>22</sup> However, these studies were conducted before the introduction of spectral-domain OCT (SD-OCT), the superior spatial resolution of which over time-domain OCT (TD-OCT)<sup>23</sup> allows for the investigation of intraretinal layers.<sup>24</sup> Previously and in particular, in the above studies, retinal alterations may have simply not been detectable by TD-OCT and, more importantly, GCIPL changes that can only be quantified using SD-OCT might be superior for detecting even subtle neurodegeneration in CIS over pRNFL. Peripapillary RNFL also failed to detect differences in our groups, suggesting that this parameter is in general less sensitive for detecting MS pathology than new intraretinal layer measurements like GCIPL. With this in mind, the failure to detect significant pRNFL alterations in our CIS-NON cohort may simply be a power issue. A third recent study comprising 45 CIS patients showed a reduction of pRNFL but not TMV using SD-OCT.<sup>25</sup>

The present study is the first to investigate intraretinal layer changes or detect retinal neurodegeneration independent from ON in a larger cohort of CIS patients. A recent study that reported reduction of the GCIPL in MS patients with and without a history of ON included seven CIS patients while the remaining patients had long-standing diagnoses of MS, which precluded reliable assessment of retinal damage in early disease stages.<sup>26</sup> Other studies have shown INL impairment (i.e. microcystic macular

oedema) in MS patients with longer disease duration.<sup>11,14</sup> Such changes were not detected in our CIS patients, suggesting that INL impairment might be a symptom of later or more severe disease stages.

Our finding that damage to the GCIPL is detectable in CIS eyes without clinical history of ON and with normal VEP latency lends additional support to the increasingly widespread understanding of MS as both a demyelinating *and* neurodegenerative disease.<sup>27</sup> We show that neurodegeneration is not, in fact, limited to advanced disease stages, in which it is considered responsible for the continuous progression of neurological disability, even in the absence of relapses. Instead, neurodegeneration can begin very early in disease development. Our data corroborate MRI data showing neuroaxonal damage during the very earliest MS stages,<sup>4,28</sup> as well as histopathology data from brain<sup>29</sup> and eye<sup>13</sup>, and from experimental autoimmune encephalomyelitis.<sup>30,31</sup> In line with previous investigations, our study provides evidence that inflammatory attacks to the optic nerve to the extent of a clinical or subclinical ON may not be a pre-requisite for damage to the retinal GCIPL.<sup>26</sup>

Our finding that neuronal retinal damage begins during very early disease stages raises urgent questions, the answers to which may challenge our understanding of the underlying pathology and mechanisms of MS.<sup>32</sup> Is the damage we found in the retina a consequence of the retrograde degeneration of retinal nerve fibers that occurs as a consequence of autoimmune brain inflammation in MS? If the answer is yes, it follows that retrograde RNFL damage would subsequently initiate a degenerative process in the GCL via a *dying back* mechanism. Indeed, the hypothesis that retrograde retinal neuroaxonal damage takes place both after ON as well as brain inflammation without clinical ON is supported by experimental animal

data from intracranial optic nerve sections.<sup>33</sup> Here, ocular pathology was shown to be limited to the inner retina. Evidence for inner retinal layer damage has been further provided by the first large scale pathological description of retinae from autopsied MS patients showing – apart from the anticipated extensive axonal damage - neuronal loss in both the GCL and the INL.<sup>13</sup> In contrast, a recent OCT study has suggested a primary retinal pathology as a novel distinct subtype of MS, which would implicate that a *dying back* pathomechanism does not apply to all patients:<sup>24</sup> The study identified MS patients exhibiting substantial reduction of TMV and significant thinning of the outer and inner nuclear layers despite normal RNFL values. The authors suggested that retinal pathology in this disease subtype (termed “macular thinning predominant”) occurs independently of optic nerve pathology and may be a harbinger of a more aggressive disease course. However, these findings have yet to be confirmed by other groups and with other OCT devices in larger cohorts.<sup>34</sup>

Some important caveats of our study should be noted. Firstly, undetected subclinical ON episodes in our patient cohort may have skewed our results. However, we dealt with this potential cohort bias swiftly by conducting a thorough clinical assessment and examination of the individual patients. Additionally, each patient had to undergo VEP: Eyes with P100 latency suspicious for ON were classified as subclinical ON and not as unaffected eyes. Furthermore, all patients received MRI as proof that a confirmed diagnosis of MS could not yet be established. Although this approach cannot be guaranteed to prevent all errors in ON identification, it does ensure that the risk of misclassification as CIS-NON or MS is negligible and that the conclusions drawn from our data are valid.

A further limitation of our study is that we could not correlate morphological data to functional visual measures such as low contrast letter acuity. However, we are

currently addressing this aspect in an ongoing CIS study that includes Sloan charts as suggested by a previous study.<sup>35</sup> The high number of statistical analyses in comparison to the relatively low number of patients should also be noted. As we did not perform a previous power calculation and since OCT parameters are related and thus likely correlated, we did not correct for multiple comparisons, since doing so would have likely caused an overcorrection. We did carefully examine our cohorts for a possible influence of outliers and distribution effects, finding no such effect. However, it is important to reproduce our findings in an independent cohort.

Segmentation of intraretinal layers is a novel technique and no studies have been performed so far to better understand how segmentation-derived results relate to in-vivo morphological changes that appear in MS (e.g. through histopathological studies). However, a number of recent studies have successfully applied intraretinal segmentation,<sup>9,14,17,26,36</sup> and comparison of different segmentation techniques showed excellent reproducibility and reliability.<sup>37</sup> We have investigated reliability of the novel algorithm applied in this study in a cross-center inter-rater reliability study on a defined set of OCT macular B-scans. Results support the excellent reliability of intraretinal segmentation reported by others,<sup>37</sup> with the exception that no histopathological correlation has been performed so far (publication in preparation). However, GCL and IPL are still difficult to differentiate in OCT scans and therefore we based our study results mostly on the combined layer of both (GCIPL) and present individual layer analyses as supplementary data only.

Of note is the large amount of eyes that were classified as suspected ON ( $n = 7$ ) in comparison to the number of eyes with definite clinical ON ( $n = 16$ ). Retinal layer thinning in these eyes was in between NON and ON eyes, further supporting the notion that optic nerve inflammation is not a *yes* or *no* event. Instead, substantial

damage might be caused by optic nerve inflammation before clinical visibility in form of an apparent clinical ON might be established. As our cohort comprised only patients with CIS, failure to detect subclinical ON potentially might compromise the discrimination between CIS patients and patients who already have definite MS. Clearly, detection of subclinical alterations in visual and other functional systems urgently needs improvement. Our study did not investigate the discriminatory properties of OCT and VEP between CIS and MS patients, and consequently, this question must be addressed by a future study.

In summary, our study shows that retinal neurodegeneration is already detectable in CIS patients and is dependent but importantly also independent of clinical relapses (i.e. ON). Accordingly, irreversible neuronal damage in MS might be much more prevalent than previously thought. Long-term follow-up of our study patients, who exhibited very early substantial and presumably irreversible neuroaxonal damage, is vital to ascertain diagnosis in patients likely to develop MS as early as possible.

## **Acknowledgements**

This study was supported by grants from the German Research Foundation (DFG Exc 257) and the German Federal Ministry of Economics and Technology (BMWi ZIM KF2286101FO9). The MS center at the Department of Neurology, Heinrich-Heine-Universität Düsseldorf, is supported in part by the Walter-and-Ilse-Rose-Stiftung (to O.A. and H.-P.H.), the Eugène Devic European Network (E-rare/EU-FP7; to O.A. and H.-P.H.), and the German Ministry for Education and Research (BMBF, "German Competence Network Multiple Sclerosis", KKNMS-BMBF; to H.-P.H.). The funding bodies neither influenced the study design, data collection and analysis, nor the decision to publish, and preparation of the manuscript.

## References

1. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008 Oct 25;372(9648):1502–1517.
2. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011 Feb;69(2):292–302.
3. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. *Lancet Neurol*. 2012 Feb;11(2):157–169.
4. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. *Brain*. 2003 Feb;126(Pt 2):433–437.
5. Rovaris M, Gambini A, Gallo A, Falini A, Ghezzi A, Benedetti B, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. *Neurology*. 2005 Nov 22;65(10):1626–1630.
6. Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, et al. Optical coherence tomography in multiple sclerosis. *Lancet Neurol*. 2006 Oct;5(10):853–863.
7. Petzold A, De Boer JF, Schippling S, Vermersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurol*. 2010 Sep;9(9):921–932.
8. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. *Ann Neurol*. 2006 Jun;59(6):963–969.



9. Albrecht P, Ringelstein M, Müller AK, Keser N, Dietlein T, Lappas A, et al. Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. *Mult Scler*. 2012 Oct 1;18(10):1422–1429.
10. Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, et al. Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. *Multiple Sclerosis International*. 2012;2012:1–10.
11. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. *Brain*. 2012 Jun;135(Pt 6):1786–1793.
12. Balk LJ, Killestein J, Polman CH, Uitdehaag BMJ, Petzold A. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. *Brain*. 2012 Dec;135(Pt 12):e226; author reply e227. doi: 10.1093/brain/aws216.
13. Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. *Brain*. 2010 Jun;133(Pt 6):1591–1601.
14. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. *Lancet Neurol*. 2012 Nov;11(11):963–972.
15. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. *Neurology*. 2007 Oct 16;69(16):1603–1609.


16. Dörr J, Wernecke KD, Bock M, Gaede G, Wuerfel JT, Pfueller CF, et al. Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis. *PLoS ONE*. 2011 Apr 8;6(4):e18132.
17. Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. *Mult Scler*. 2012. doi:10.1177/1352458512457844.
18. Pfueller CF, Brandt AU, Schubert F, Bock M, Walaszek B, Waiczies H, et al. Metabolic Changes in the Visual Cortex Are Linked to Retinal Nerve Fiber Layer Thinning in Multiple Sclerosis. *PLoS ONE*. 2011 Apr 6;6(4):e18019.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology*. 1983 Nov;33(11):1444–1452.
20. Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C. Subclinical Visual Involvement in Multiple Sclerosis: A Study by MRI, VEPs, Frequency-Doubling Perimetry, Standard Perimetry, and Contrast Sensitivity. *IOVS*. 2005 Jan 4;46(4):1264–1268.
21. Outteryck O, Zephir H, Defoort S, Bouyon M, Debruyne P, Bouacha I, et al. Optical coherence tomography in clinically isolated syndrome: no evidence of subclinical retinal axonal loss. *Arch Neurol*. 2009 Nov;66(11):1373–1377.
22. Kallenbach K, Sander B, Tsakiri A, Wanscher B, Fuglø D, Larsen M, et al. Neither retinal nor brain atrophy can be shown in patients with isolated unilateral optic neuritis at the time of presentation. *Mult Scler*. 2011 Jan;17(1):89–95.
23. Bock M, Brandt AU, Dorr J, Pfueller CF, Ohlraun S, Zipp F, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. *Multiple Sclerosis*. 2010 Mar;16(7):893–896.

24. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. *Brain*. 2011 Feb;134(Pt 2):518–533.
25. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes. *PLoS ONE*. 2012 May 23;7(5):e36847.
26. Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. *Brain*. 2012 Feb;135(Pt 2):521–533.
27. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. *Trends Neurosci*. 2006 Sep;29(9):518–527.
28. Sbardella E, Tomassini V, Stromillo ML, Filippini N, Battaglini M, Ruggieri S, et al. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler*. 2011 Dec;17(12):1432–1440.
29. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. *N Engl J Med*. 2011 Dec 8;365(23):2188–2197.
30. Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. *Ann Neurol*. 2009 Sep;66(3):310–322.

31. Fairless R, Williams SK, Hoffmann DB, Stojic A, Hochmeister S, Schmitz F, et al. Preclinical retinal neurodegeneration in a model of multiple sclerosis. *J Neurosci*. 2012 Apr 18;32(16):5585–5597.
32. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. *N Engl J Med*. 1998 Jan 29;338(5):278–285.
33. Holländer H, Bisti S, Maffei L, Hebel R. Electroretinographic responses and retrograde changes of retinal morphology after intracranial optic nerve section. A quantitative analysis in the cat. *Exp Brain Res*. 1984;55(3):483–493.
34. Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. *Brain*. 2011 Nov;134(Pt 11):e193; author reply e194.
35. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. *Neurology*. 2003 Nov 25;61(10):1367–1373.
36. Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. *Multiple Sclerosis Journal*. 2011 Dec 1;17(12):1449 – 1463.
37. Seigo M, Sotirchos E, Newsome S, Babiarz A, Eckstein C, Ford E, et al. In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. *J Neurol*. 2012 Oct 1;259(10):2119–2130.

## Figures


Figure 1: Examples of regions analyzed in OCT.



A) Scanning laser ophthalmoscopy image showing the region of the peripapillary ring scan (green); B) Scanning laser ophthalmoscopy image of the macular scan with the blue circle indicating the area for total macular volume and intraretinal layer thickness determination; C) 3D reconstruction of a macular volume scan, depicting the identified intraretinal layers.

Abbreviations: RNFL = retinal nerve fiber layer; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; ELM=external limiting membrane; IS/OS = inner segments / outer segments; RPE = retinal pigment epithelium.

Figure 2: VEP and standard OCT results.




Scatterplots showing the relationship of the VEP P100 latencies with A) peripapillary RNFL (pRNFL) and B) total macular volume. The red dashed line at 115 ms indicates the threshold between CIS-NON and CIS-SON eyes. The black line is the result of the linear regression including all CIS eyes with the standard error given as gray shadow. Comparison of C) peripapillary RNFL thickness and D) total macular volume

between the different CIS groups and the matching controls. Significant differences are marked with \* ( $P < 0.05$ ), \*\* ( $P < 0.01$ ) and \*\*\* ( $P < 0.001$ ).

Abbreviations: HC = healthy control eyes; CIS-NON = patient eyes without history of optic neuritis and VEP P100  $\leq 115$  ms; CIS-SON = eyes with VEP P100 latency  $> 115$  ms but no ON diagnosis; CIS-ON = patient eyes with clinical ON diagnosis.

Figure 3: Spatial analysis of changes in CIS eyes versus healthy control eyes.



A) Changes in RNFL thickness between CIS patients and the corresponding group of age- and sex-matched healthy controls. Patients were stratified by history of ON: no



history of ON (NON), suspected ON (SON) or clinically diagnosed ON. Reduction in RNFL thickness was evident near the optic nerve head (white arrows) in all groups but was more pronounced in SON and ON eyes. B) Thickness changes in the GCIPL were identified in the perimacular region and were most evident in CIS-ON eyes. Significant thinning of the GCIPL in CIS-NON eyes compared to the matching controls were found in the perimacular area ( $P = 0.027$ ). C) No group showed significant changes in the INL.

Abbreviations: CIS = clinically isolated syndrome; RNFL = retinal nerve fiber layer; GCIPL = combined ganglion cell and inner plexiform layer; INL = inner nuclear layer.